Title

Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients
A Randomized, Double-blinded, Placebo-controlled Study on the Effects of Adalimumab Intralesional Intestinal Strictures of Crohn's Disease Patients
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Status

    Terminated
  • Intervention/Treatment

    adalimumab ...
  • Study Participants

    26
We study if the administration of intralesional Adalimumab (directly injected in the stricture) associated to endoscopic dilatation has a higher success rate at week 8 compared with placebo in patients with Crohn's disease who had confirmed intestinal stenosis (3 stenosis as maximum)
Study Started
Feb 14
2014
Primary Completion
Jun 30
2018
Study Completion
Jun 30
2018
Last Update
Dec 13
2018

Drug Adalimumab

single intralesional administration during endoscopy process

Drug placebo

single intralesional administration during endoscopy

Adalimumab Experimental

single administration of Adalimumab 80mg diluted in 5ml saline

saline Placebo Comparator

5 ml of saline

Criteria

Inclusion Criteria:

Patients of both sexes older than 18 years
Patient diagnosed of CROHN´s disease
Patient with intestinal stenosis length equal or less than 5cm previously confirmed with bowel magnetic resonance imaging (3 stenosis as maximum)
Stenosis no permeable for endoscopy(12mm in case of accessible stenosis with conventional colonoscopy and 10mm in case of accessible stenosis with balloon enteroscopy)
Dilated stenosis according to endoscopist criteria (pass or no the endoscopy)
Patient capable of participate in the examinations required by the study
Patient after being informed, give his/her informed consent in writing

Exclusion Criteria:

Patients with large intestinal stenosis (more than 6cm) and multiples
Patients with previous or actual treatment with anti-tumor necrosis factor (anti-TNF) drugs
Patients with positive serology to hepatitis B virus(HBV),hepatitis C virus (HCV), or HIV
Patients with positive screening to Tuberculosis(positive PPD)
Established contraindication to anti-TNF drugs
Existence of fistulous tracts associated with intestinal stenosis
Neoplastic process associated with stenosis or in another location
Pregnancy or breastfeeding
No Results Posted